- Home
- APVO vs INM Comparison
APVO vs INM Comparison
Compare APVO & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- INM
- Stock Information
- Founded
- APVO 2016
- INM 1981
- Country
- APVO United States
- INM Canada
- Employees
- APVO N/A
- INM N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- INM Health Care
- Exchange
- APVO Nasdaq
- INM Nasdaq
- Market Cap
- APVO 4.9M
- INM 4.3M
- IPO Year
- APVO N/A
- INM N/A
- Fundamental
- Price
- APVO $1.78
- INM $2.28
- Analyst Decision
- APVO
- INM
- Analyst Count
- APVO 0
- INM 0
- Target Price
- APVO N/A
- INM N/A
- AVG Volume (30 Days)
- APVO 16.3M
- INM 93.9K
- Earning Date
- APVO 11-06-2025
- INM 11-13-2025
- Dividend Yield
- APVO N/A
- INM N/A
- EPS Growth
- APVO N/A
- INM N/A
- EPS
- APVO N/A
- INM N/A
- Revenue
- APVO N/A
- INM $4,942,633.00
- Revenue This Year
- APVO N/A
- INM N/A
- Revenue Next Year
- APVO N/A
- INM N/A
- P/E Ratio
- APVO N/A
- INM N/A
- Revenue Growth
- APVO N/A
- INM 7.50
- 52 Week Low
- APVO $1.32
- INM $1.72
- 52 Week High
- APVO $381.10
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- APVO 53.33
- INM 49.66
- Support Level
- APVO $1.41
- INM $2.17
- Resistance Level
- APVO $1.49
- INM $2.30
- Average True Range (ATR)
- APVO 0.18
- INM 0.12
- MACD
- APVO 0.04
- INM 0.01
- Stochastic Oscillator
- APVO 35.04
- INM 41.16
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.